RxDoctor Payments Data

Fares Alsawah, MD

Internal Medicine · Ann Arbor, MINPI 1497174551

Payments from drug & device makers

$6,467in general payments, 2019–2025

Across 216 payments — averaging $29.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$2K
  • AbbVie$390
  • AstraZeneca$351
  • Gilead$329
  • Astellas Pharma US Inc$308
  • Merck$264
  • plus $3K from 37 others

What the payments were for

  • Food & beverage$4,54270%
  • Education$74412%
  • Other$1,18018%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,467 in reported general payments places this provider in the 90th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$2,695,531
Medicare patients
359
Services billed
126,158

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide46$509,039
BrukinsaZanubrutinib13$189,812
VerzenioAbemaciclib13$189,572
Lenalidomide13$184,986
ProcritEpoetin Alfa15$38,029
EliquisApixaban30$21,073
VeozahFezolinetant24$12,549
Toremifene Citrate12$11,344
Anastrozole138$3,015
Tamoxifen Citrate47$2,056
Dabigatran EtexilateDabigatran Etexilate Mesylate12$1,724
Exemestane14$1,352
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen72$1,024
Morphine Sulfate ErMorphine Sulfate31$667
Alendronate Sodium52$356

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Veozah$308$521,58770 claims
Beigene USA, Inc.Brukinsa$68$189,81213 claims
Lilly USA, LLCVerzenio, Olanzapine$115$189,63927 claims
Johnson & JohnsonProcrit$148$38,02915 claims
PfizerEliquis$240$21,07330 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Ann Arbor

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →